Jason Hoffman, PharmD, RPh

Most Recent Articles by Jason Hoffman, PharmD, RPh

Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal

Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal

By

Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).

Olaparib Improves PFS in <i>BRCA</i>-mutant Breast Cancer

Olaparib Improves PFS in BRCA-mutant Breast Cancer

By

Olaparib significantly prolonged progression-free survival compared with chemotherapy among patients with HER2-negative breast cancer.

Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

By

Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.

Genomic Alterations in Metastatic Renal Cell Carcinoma

Genomic Alterations in Metastatic Renal Cell Carcinoma

By

Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

By

Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.

More Articles by Jason Hoffman, PharmD, RPh

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters